 In the pivotal phase III trial, the combination of gemcitabine plus erlotinib was associated with a statistically significant prolongation of OS compared to single-agent gemcitabine, however, the absolute survival benefit was - for the overall study population - clinically moderate median OS: 6.24 vs 5.91 months, 1-year OS rate: 23 vs 17; HR 0.82, p0.038 Moore 2007 19. 